Market Access Impact: Rheumatoid Arthritis (US) 2017

Who wins and loses when brands struggle with cost barriers and limited market access?

Market barriers affect just over 20 percent of rheumatoid arthritis (RA) prescriptions in the US. High costs and limited formulary access are preventing rheumatologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand?

Get the answers in Market Access Impact: Rheumatoid Arthritis (US).

Based on a survey of 100 rheumatologists, the report covers 11 major therapies from AbbVie, Amgen, Bristol-Myers Squibb, Janssen Biotech, Regeneron, Sanofi, Pfizer, Roche, and UCB. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Not your market? Click here to see the EU5 Edition.

Request sample pages

• Nearly all brands are widely prescribed. Over 80% or more of the doctors surveyed prescribe nine of the 11 brands covered, and 100% prescribe the top brand.
• Five brands gain share. Two of them gain significantly, another gains moderate share and the other two barely gain at all.
• Biosimilars are struggling to have an impact. The most prescribed biosimilar is prescribed by just over a third of physicians, but removing barriers could double that.
• Eliminating barriers would have an equal impact at the top and bottom of the market. Leaders and laggards would either lose or gain market share, respectively, in a barrier free world.
• Prescribing challenges not related to perception problems. Surveyed doctors have good awareness of all surveyed brands.
• Market access is not the problem. Barriers related to market access affect far fewer prescriptions than either of the top two barriers.

• Actemra (tocilizumab; Roche)
• Cimzia (certolizumab pegol; UCB)
• Enbrel (etanercept; Amgen)
• Humira (adalimumab; AbbVie)
• Inflectra (infliximab; Pfizer)
• Kevzara (sarilumab; Sanofi/Regeneron)
• Orencia (abatacept; Bristol-Myers Squibb)
• Remicade (infliximab; Janssen Biotech)
• Rituxan (rituximab; Roche/Biogen)
• Simponi (golimumab; Janssen Biotech)
• Xeljanz (tofacitinib; Pfizer)

Market Access Impact: Rheumatoid Arthritis (US) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

• What brands do doctors prescribe the most?
• How many prescriptions do barriers affect?
• Which barriers have the biggest impact?

How barriers affect your brand:

• How many doctors prescribe your brand? How many don’t, but would consider it?
• Why don’t doctors prescribe your brand? What do they prescribe instead?
• Which competing brands does your brand take market share from?

We surveyed 100 US-based rheumatologists, chosen from the largest community of validated physicians in the world.

All respondents have:

• Been practicing for 2+ years
• Prescribed at least one of the listed products
• Seen at least 5 patients with RA in total in the last month

We conducted the survey between November 3-9, 2017.

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

• FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
• FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.